Supplemental BLA accepted; masseter prominence treatment moves closer to approval.
The FDA accepted AbbVie's supplemental Biologics License Application (sBLA) for BOTOX Cosmetic in the treatment of jawline prominence (masseter hypertrophy). The acceptance signals the agency is reviewing the clinical data and moving the indication toward potential approval.
For medspa owners, a new BOTOX indication expands the addressable market and creates a new revenue stream. Masseter treatment is already performed off-label by many practices, but FDA approval legitimizes the indication, supports marketing, and may unlock insurance coverage in some cases. AbbVie will likely support the approval with educational campaigns and Allē rebates tied to masseter volume.
Supplemental BLA accepted; masseter prominence treatment moves closer to approval.
The timing matters: if approval comes in late 2026 or 2027, you have time to train staff and build patient awareness. However, off-label masseter Botox is already competitive—Jeuveau, Xeomin, and other toxins are used for this indication. An FDA approval does not guarantee market share; it levels the playing field and may compress per-unit pricing as volume scales.
Source: original report ↗
Frequently asked questions
Can I legally use BOTOX for jawline/masseter treatment right now?
Yes, masseter BOTOX is already performed off-label by many practices today. However, FDA approval for this indication is still pending—AbbVie's supplemental BLA was recently accepted for review. Once approved (expected late 2026 or 2027), the indication will be officially labeled, which strengthens marketing claims and may unlock insurance coverage.
Will FDA approval of BOTOX for masseter treatment increase my revenue?
FDA approval creates a new revenue stream and expands your addressable market, but it also intensifies competition. Competitors like Jeuveau and Xeomin already treat masseter off-label, so approval levels the playing field rather than guarantees market dominance. Expect increased patient awareness but potential per-unit pricing pressure as volume scales.
What should I do to prepare for BOTOX masseter approval?
Start training staff now on masseter anatomy, injection technique, and patient selection. Build patient awareness through content and consultations about jawline contouring. Watch for AbbVie's educational campaigns and Allē rebate programs tied to masseter volume, which will likely launch around approval.
Will insurance cover BOTOX for masseter treatment after FDA approval?
FDA approval may unlock insurance coverage in some cases, particularly if masseter hypertrophy causes functional issues like TMJ pain or bruxism. However, coverage will vary by plan and region. Off-label use today is almost always out-of-pocket, so approval could shift some volume to insured patients depending on your payer mix.
How does BOTOX masseter approval affect pricing strategy?
Expect competitive pricing pressure as the indication becomes mainstream and volume increases across the market. AbbVie will likely support adoption with Allē rebates and educational campaigns, which can help offset margin compression. Positioning masseter BOTOX as part of a comprehensive jawline package (combining injectables, fillers, or other modalities) can protect margins.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
